2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Bioinformatics, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Diseases, Infectious Diseases, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, AML, APL, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

5131 Long term clinical outcomes and relapse patterns of KMT2A rearranged AML patients

Yuchen Liu, MD, Jack Shapiro, MD2, Himachandana Atluri, MD3, Madina Sukhanova4, Irum Khan, MD5, Shira Dinner, MD6, Yasmin Abaza, MD7, Jessica Kaplan Altman, MD8
1 Northwestern University Feinberg School of Medicine, Chicago, United States
2 Northwestern University Feinberg School of Medicine, Chicago, United States
3 Northwestern University Feinberg School of Medicine, Chicago, United States
4 Northwestern University Feinberg School of Medicine, Chicago, United States
5 Northwestern University Feinberg School of Medicine, Chicago, United States
6 Northwestern University Feinberg School of Medicine, Chicago, United States
7 Northwestern University Feinberg School of Medicine, Chicago, United States
8 Northwestern University Feinberg School of Medicine, Chicago, United States

Introduction:

KMT2A fusions involving chromosome 11q23 are recurrent abnormalities seen in acute myeloid leukemia (AML) and represent a high-risk subtype. The development of KMT2A fusions can be seen both in in de novo and therapy related AML (tAML) notably after exposure to anthracycline. Venetoclax (VEN) based treatment and revumenib, approved for patients with relapsed and refractory KMT2A rearranged (KMT2Ar) acute leukemias in 2024 have provided additional therapeutic options for patients with this challenging disease. Despite these advancements, relapses and treatment resistance are still common which prompted us to evaluate the clinicopathologic of these patients to identify unique biologic characteristics of this subtype to serve as the basis for development of novel future combinations and therapeutics.

Methods:

Here we present the clinical and pathologic correlates of adult patients with AML KMT2A fusions that were treated at a single academic institution from December 2008 to October 2025. After IRB approval, we identified 62 AML patients with KMT2Ar through our pathology core. Comprehensive molecular and clinicopathologic data was obtained through review of their medica records. Overall survival was determined based time from diagnosis to last follow up or death. Survival was estimated using Kaplan-Meier method.

Results:

A total of 62 patients were evaluated with KMT2Ar AML. Included patients had a median age of 46.5 (range 18-82), 54.8% (n=34) were female, 71% (n=44) were White with remainder (8% Black, 6.5% Asian, 3.2% Hispanic, 11.3% Unknown). 56.5% (n=35) patients had tAML and 45.2% (n=28) with t(9;11). NGS was performed in 69.4% (n=43) patients with co-mutations in K/NRAS (34.8%), PTPN11 (13.9%), FLT3-TKD (8.9%), and TP53 (6.7%) most commonly identified.

19.6% (n=12) of patients with clinical information available at diagnosis were identified to have extramedullary disease (EMD) with skin as the most common site. 52.5% of patients (n=32) underwent screening lumbar puncture identifying central nervous system (CNS) involvement in 18.8% (n=6).

Patients underwent treatment with either intensive chemotherapy (IC) (n=37), IC with VEN (n=7), IC with menin inhibitor on trial (n=3) or lower intensity therapy (n=14). One patient did not receive therapy. 69.3% (n = 43) of patients underwent allogeneic stem cell transplant (alloSCT). Median overall survival (mOS) was 15.4 months (13.3 – 100.9). mOS was not reached (NR) in patients receiving IC with ven (CI 14.6 – NR months) or menin inhibitor (CI 6.9 – NR) up front. In patients receiving intensive chemotherapy without targeted inhibition, mOS was 21.4 months (CI 14.5 – NR) and was 5.9 months (CI 3.5 – NR) in those receiving lower intensity therapy. mOS was improved for patients who underwent alloSCT with mOS of 30.2 months (CI 16.9 – NR) compared to 6.15 months (CI 5.4 – 14.6) without alloSCT (p<0.001).

Relapses and disease progression (based on IWG criteria) were common and noted in 48.4% (n = 30) of patients. 53.3% (n=16) of patients had EMD at relapse or disease progression with 30% (n=9) patients having EMD relapse detected only at relapse. After alloSCT, 32.6% (n=14) of patients were noted to have relapsed within 2 years. Notably, the 68.8% (n=11) of relapses occurred early within the first 6 months after alloSCT but also 2 patients had a late relapse occurring 5+ years after alloSCT. Finally, acquisition of mutations in K/NRAS (n=5), TP53 (n=3), and PTPN11 (n=2) were the most commonly identified at the time of relapse.

Conclusion:

Here we characterize a longitudinal set of patients with KMT2A rearranged patients with AML treated at our center and identify relatively high rates EMD and CNS involvement. Relapses occur frequently with this known high risk subtype of AML, which can occur rapidly after an alloSCT with the majority of post-transplant relapses occurring in the first 6 months, but late relapses can also occur. A relatively high proportion of RAS activating mutations that are detected both at diagnosis and acquired at disease progression or relapse, provide the potential of a future target for patients with this high risk subtype of AML.

 

Yuchen Liu, MD: Maplight Therapeutics - Current equity holder in publicly-traded company; Regeneron - Stock (publicly traded); Maplight Therapeutics - Stock (publicly traded); Cormedix - Stock (publicly traded); Absci Corporation - Stock (publicly traded); Axsome Therapeutics - Stock (publicly traded); Fate Therapeutics Inc - Stock (publicly traded); Maplight Therapeutics - Current Employment